1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Sickle Cell Disease-Pipeline Insights, 2016

Sickle Cell Disease-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Sickle Cell Disease-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Sickle Cell Disease. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Sickle Cell Disease. DelveInsight’s Report also assesses the Sickle Cell Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Sickle Cell Disease
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Sickle Cell Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Sickle Cell Disease and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Sickle Cell Disease-Pipeline Insights, 2016

Illustrative Table of contents

- Sickle Cell Disease Overview
- Sickle Cell Disease Pipeline Therapeutics
- Sickle Cell Disease Therapeutics under Development by Companies
- Sickle Cell Disease Filed and Phase III Products
- Comparative Analysis
- Sickle Cell Disease Phase II Products
- Comparative Analysis
- Sickle Cell Disease Phase I and IND Filed Products
- Comparative Analysis
- Sickle Cell Disease Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Sickle Cell Disease - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Sickle Cell Disease - Discontinued Products
- Sickle Cell Disease - Dormant Products
- Companies Involved in Therapeutics Development for Sickle Cell Disease
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Sickle Cell Disease, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Sickle Cell Disease Assessment by Monotherapy Products
- Sickle Cell Disease Assessment by Combination Products
- Sickle Cell Disease Assessment by Route of Administration
- Sickle Cell Disease Assessment by Stage and Route of Administration
- Sickle Cell Disease Assessment by Molecule Type
- Sickle Cell Disease Assessment by Stage and Molecule Type
- Sickle Cell Disease Therapeutics - Discontinued Products
- Sickle Cell Disease Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Sickle Cell Disease, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Sickle Cell Disease Assessment by Monotherapy Products
- Sickle Cell Disease Assessment by Combination Products
- Sickle Cell Disease Assessment by Route of Administration
- Sickle Cell Disease Assessment by Stage and Route of Administration
- Sickle Cell Disease Assessment by Molecule Type
- Sickle Cell Disease Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.